Multicenter Phase 2 Trial of Cis/Carboplatin, nAb-Paclitaxel, and CeTUXimab (CACTUX) as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

被引：2
|
作者：
Adkins, D. [1 ]
Ley, J. [2 ]
Atiq, O. [3 ]
Rigden, C. [2 ]
Trinkaus, K. [2 ]
Wildes, T. M. [2 ]
Oppelt, P. [2 ]
机构：
[1] Washington Univ, Dept Med Oncol, St Louis, MO USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2018年 / 100卷 / 05期
关键词：
D O I：
10.1016/j.ijrobp.2017.12.029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9
引用
收藏
页码：1311 / 1312
页数：3
相关论文
共 50 条
  • [1] Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.
    Bhatia, Aarti K.
    Mehra, Ranee
    Khan, Saad A.
    Egleston, Brian L.
    Alpaugh, R. Katherine
    Lango, Miriam
    Ridge, John A.
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung
    Yang, Jin-Ji
    Huang, Cheng
    Chen, Gong-Yan
    Song, Yong
    Cheng, Ying
    Yan, Hong-Hong
    Zhou, Qing
    Wu, Yi-Long
    BMC CANCER, 2014, 14
  • [3] A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung
    Jin-Ji Yang
    Cheng Huang
    Gong-Yan Chen
    Yong Song
    Ying Cheng
    Hong-Hong Yan
    Qing Zhou
    Yi-Long Wu
    BMC Cancer, 14
  • [4] Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial*
    Adkins, Douglas
    Ley, Jessica
    Atiq, Omar
    Powell, Steven
    Spanos, William C.
    Gitau, Mark
    Rigden, Caron
    Palka, Kevin
    Liu, Jingxia
    Oppelt, Peter
    ORAL ONCOLOGY, 2021, 115
  • [5] Mature follow up of induction chemotherapy with carboplatin, nab-paclitaxel, cetuximab in head and neck squamous cell carcinoma
    Sheth, Siddharth
    Gilbert, Jill
    Deal, Allison Mary
    Chera, Bhishamjit
    Murphy, Barbara
    Woods, Justin
    Miller, Kelsey
    Weissler, Mark
    Hackman, Trevor
    Liao, Jay Justin
    Olson, Juneko Grilley
    Hayes, David Neil
    Weiss, Jared
    ORAL ONCOLOGY, 2022, 127
  • [6] CARBOPLATIN, PACLITAXEL AND PEMBROLIZUMAB FOR THE FIRST LINE TREATMENT OF RECURRENT AND/OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Valadez, Angelica
    Welsh, Madeleine
    Kim, Christine
    Johns, Angela
    Algazi, Alain
    Kang, Hyunseok
    Kang, Hyunseok
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A118 - A118
  • [7] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
    Hitt, R.
    Irigoyen, A.
    Cortes-Funes, H.
    Grau, J. J.
    Garcia-Saenz, J. A.
    Cruz-Hernandez, J. J.
    ANNALS OF ONCOLOGY, 2012, 23 (04) : 1016 - 1022
  • [8] Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)
    Tahara, M.
    Kiyota, N.
    Yokota, T.
    Hasegawa, Y.
    Muro, K.
    Takahashi, S.
    Onoe, T.
    Homma, A.
    Taguchi, J.
    Suzuki, M.
    Minato, K.
    Yane, K.
    Ueda, S.
    Hara, H.
    Saijo, K.
    Yamanaka, T.
    ANNALS OF ONCOLOGY, 2018, 29 (04) : 1004 - 1009
  • [9] A phase II trial of first-line nab-paclitaxel/carboplatin versus gemcitabine/carboplatin in advanced squamous cell carcinoma of the lung (CTONG1002)
    Yang, Jinji
    Huang, Cheng
    Song, Yong
    Cheng, Ying
    Chen, Gongyan
    Yan, Hong-Hong
    Zhou, Qing
    Chen, Huajun
    Ben, Xiao-song
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Bossi, P.
    Miceli, R.
    Locati, L. D.
    Ferrari, D.
    Vecchio, S.
    Moretti, G.
    Denaro, N.
    Caponigro, F.
    Airoldi, M.
    Moro, C.
    Vaccher, E.
    Sponghini, A.
    Caldara, A.
    Rinaldi, G.
    Ferrau, F.
    Nole, F.
    Lo Vullo, S.
    Tettamanzi, F.
    Hollander, L.
    Licitra, L.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2820 - 2826
12345